428 related articles for article (PubMed ID: 20937904)
1. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
Sevrioukova IF; Poulos TL
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
[TBL] [Abstract][Full Text] [Related]
2. Interaction of human cytochrome P4503A4 with ritonavir analogs.
Sevrioukova IF; Poulos TL
Arch Biochem Biophys; 2012 Apr; 520(2):108-16. PubMed ID: 22410611
[TBL] [Abstract][Full Text] [Related]
3. Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.
Sevrioukova IF; Poulos TL
J Med Chem; 2013 May; 56(9):3733-41. PubMed ID: 23586711
[TBL] [Abstract][Full Text] [Related]
4. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
Sevrioukova IF; Poulos TL
Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
[TBL] [Abstract][Full Text] [Related]
5. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
[TBL] [Abstract][Full Text] [Related]
6. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP
J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478
[TBL] [Abstract][Full Text] [Related]
7. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Loos NHC; Beijnen JH; Schinkel AH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
[TBL] [Abstract][Full Text] [Related]
8. Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.
Samuels ER; Sevrioukova I
Biochemistry; 2019 Apr; 58(15):2077-2087. PubMed ID: 30912932
[TBL] [Abstract][Full Text] [Related]
9. Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Nookala AR; Li J; Ande A; Wang L; Vaidya NK; Li W; Kumar S; Kumar A
PLoS One; 2016; 11(1):e0146529. PubMed ID: 26741368
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic enhancers for HIV drugs.
Xu L; Desai MC
Curr Opin Investig Drugs; 2009 Aug; 10(8):775-86. PubMed ID: 19649922
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.
Guengerich FP; McCarty KD; Chapman JG
J Biol Chem; 2021; 296():100223. PubMed ID: 33449875
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
14. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.
Sevrioukova IF; Poulos TL
Biochemistry; 2013 Jul; 52(26):4474-81. PubMed ID: 23746300
[TBL] [Abstract][Full Text] [Related]
15. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
Hsu MH; Johnson EF
J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
[TBL] [Abstract][Full Text] [Related]
16. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
Samuels ER; Sevrioukova IF
Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
[TBL] [Abstract][Full Text] [Related]
17. Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors.
Gass RJ; Gal J; Fogle PW; Detmar-Hanna D; Gerber JG
Eur J Clin Pharmacol; 1998; 54(9-10):741-7. PubMed ID: 9923578
[TBL] [Abstract][Full Text] [Related]
18. Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution.
Chuo SW; Liou SH; Wang LP; Britt RD; Poulos TL; Sevrioukova IF; Goodin DB
Biochemistry; 2019 Sep; 58(37):3903-3910. PubMed ID: 31456404
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
Kaur P; Chamberlin AR; Poulos TL; Sevrioukova IF
J Med Chem; 2016 May; 59(9):4210-20. PubMed ID: 26371436
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
